论文部分内容阅读
目的：探讨恶性卵巢肿瘤组织中ＣＤ４４ｖ９ 基因表达及其临床意义。方法：用ＲＴ－ ＰＣＲ 方法检测了４１ 例恶性卵巢肿瘤、２０ 例良性卵巢肿瘤和２１ 例正常卵巢组织中ＣＤ４４ｖ９ 基因表达情况并分析相关的临床病理因素。结果：１）ＣＤ４４ｖ９ 基因表达阳性率恶性组明显高于良性组和正常组，良性组高于正常组；２）ＣＤ４４ｖ９ 基因表达在有转移者阳性率显著高于无转移者，转移灶阳性率高于原发灶；３）ＣＤ４４ｖ９ 阳性表达率与临床期别有一定关系，但与病理类型、组织学级别、预后无关。结论：１）ＣＤ４４ｖ９ 基因与肿瘤的发生、发展相关；２）ＣＤ４４ｖ９ 与卵巢恶性肿瘤的浸润和转移相关，可以作为预测肿瘤转移潜能指标。
Objective: To investigate the expression of CD44v9 gene in malignant ovarian tumor and its clinical significance. Methods: The expression of CD44v9 in 41 cases of malignant ovarian tumors, 20 cases of benign ovarian tumors and 21 cases of normal ovarian tissues was detected by RT-PCR and the related clinicopathological factors were analyzed. Results: 1) The positive rate of CD44v9 gene expression in malignant group was significantly higher than that in benign group and normal group, while that in benign group was higher than that in normal group. 2) The positive rate of CD44v9 gene in metastatic group was significantly higher than that in non-metastatic group In primary tumor; 3) The positive rate of CD44v9 was related to the clinical stage, but not to the pathological type, histological grade and prognosis. Conclusions: 1) CD44v9 gene is associated with the occurrence and development of cancer; 2) CD44v9 is associated with invasion and metastasis of ovarian cancer and may be used as an index to predict tumor metastasis potential.